A recent study published in JAMA Network Open suggests biologics filgrastim, pegfilgrastim, infliximab and insulin glargine all saw their prices drop in response to biosimilar competition.
The study by University of Pittsburgh School of Pharmacy’s Alvaro San-Juan-Rodriguez et al. analyzed pricing data from SSR Health, according to a Healio report.
“Biosimilar prices are estimated to be 15% to 16% lower than originator products, but it is unclear how list prices, net prices and discounts for the originator products change with biosimilar competition,” the researchers wrote.
To read more on Healio, click here.